Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.64 |
| ▸ | EP300 | Q09472 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.60 |
| ▸ | CCR2 | P41597 | 1/20 | 0.55 |
| ▸ | ACLY | P53396 | 13/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13510477 | 0.88 | HSD11B1 (0.60) | HSD11B1EP300BRAFACLYPTK2B | |
| SCHEMBL13510432 | 0.88 | HSD11B1 (0.63) | HSD11B1EP300BRAFCCR2ACLY | |
| SCHEMBL13510527 | 0.87 | HSD11B1 (0.68) | HSD11B1EP300BRAFACLY | |
| SCHEMBL13510467 | 0.86 | EP300 (0.61) | HSD11B1EP300BRAFCCR2ACLY | |
| SCHEMBL16137365 | 0.84 | HSD11B1 (0.79) | HSD11B1EP300BRAFKDM4ESMN1; SMN2 | |
| SCHEMBL13510521 | 0.84 | EP300 (0.68) | HSD11B1EP300BRAFACLY | |
| SCHEMBL13510423 | 0.82 | EP300 (0.59) | HSD11B1EP300BRAFSMN1; SMN2 | |
| SCHEMBL13510452 | 0.82 | EP300 (0.69) | HSD11B1EP300BRAF | |
| SCHEMBL13510463 | 0.82 | HSD11B1 (0.68) | HSD11B1EP300BRAFACLYKDM4E | |
| SCHEMBL13510464 | 0.81 | HSD11B1 (0.63) | HSD11B1EP300BRAFACLYKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161831-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | BAYLOR COLLEGE OF MEDICINE (US) | 2021-11-02 | — | — | US | disclosed |
| WO-2021113551-A1 | THERAPEUTIC COMPOUNDS FOR METHODS OF USE IN INSULIN RESISTANCE | BAYLOR COLLEGE OF MEDICINE (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20200331880-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2020-10-22 | — | — | US | disclosed |
| US-10676455-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | BAYLOR COLLEGE OF MEDICINE (US) | 2020-06-09 | — | — | US | disclosed |
| US-20150051233-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS | BAYLOR COLLEGE OF MEDICINE | 2015-02-19 | — | — | US | disclosed |
| US-20150051233-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS | BAYLOR COLLEGE OF MEDICINE | 2015-02-19 | — | — | US | disclosed |
| US-20150031714-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION | BAYLOR COLLEGE OF MEDICINE | 2015-01-29 | — | — | US | disclosed |
| US-20150031714-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION | BAYLOR COLLEGE OF MEDICINE | 2015-01-29 | — | — | US | disclosed |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2015-01-22 | — | — | US | disclosed |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2015-01-22 | — | — | US | disclosed |
| US-20140296270-A1 | STAT3 Inhibitors | BAYLOR COLLEGE OF MEDICINE (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296270-A1 | STAT3 Inhibitors | BAYLOR COLLEGE OF MEDICINE (US) | 2014-10-02 | — | — | US | disclosed |
| US-8779001-B2 | Stat3 inhibitors | The United States of America National Institute of Health (NIH) (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779001-B2 | Stat3 inhibitors | The United States of America National Institute of Health (NIH) (US) | 2014-07-15 | — | — | US | disclosed |
| US-20110312984-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-12-22 | — | — | US | disclosed |
| US-20110312984-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-12-22 | — | — | US | disclosed |
| US-20100041685-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| US-20100041685-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| WO-2009149192-A1 | STAT3 INHIBITORS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051233-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS | STAT3, MMP1, MMP8 | HSD11B1 2096/4885EP300 35/4885BRAF 1327/4885 |
| US-10676455-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | PYGM, MYLK2, STAT3 | HSD11B1 2340/4885EP300 158/4885BRAF 2814/4885 |
| US-11161831-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | PYGM, MYLK2, STAT3 | HSD11B1 2340/4885EP300 158/4885BRAF 2814/4885 |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | PYGM, MYLK2, STAT3 | HSD11B1 2340/4885EP300 158/4885BRAF 2814/4885 |
| US-20100041685-A1 | STAT3 INHIBITORS | STAT3, STAT1, JAK2 | HSD11B1 3658/4885EP300 223/4885BRAF 650/4885 |
| US-20200331880-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | PYGM, MYLK2, STAT3 | HSD11B1 2340/4885EP300 158/4885BRAF 2814/4885 |
| US-20140296270-A1 | STAT3 Inhibitors | STAT3, STAT1, JAK2 | HSD11B1 3658/4885EP300 223/4885BRAF 650/4885 |
| US-20150031714-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION | JAK2, STAT3, STAT6 | HSD11B1 1764/4885EP300 95/4885BRAF 1379/4885 |
| US-20110312984-A1 | STAT3 INHIBITORS | STAT3, STAT1, JAK2 | HSD11B1 3658/4885EP300 223/4885BRAF 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.